GSK falls as blood cancer drug likely headed for US rejection
(Reuters) -GSK shares fell more than 6% on Friday to the bottom of Britain’s blue-chip index after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over side effects. The British drugmaker was trying to revive the drug, which was pulled from U.S. markets in 2022 after failing …
GSK falls as blood cancer drug likely headed for US rejection Read More »










